Status
Conditions
Treatments
Study type
Funder types
Identifiers
About
The aim of TIMEDIAB is to demonstrate that early TRE (eTRE) combined to late (afternoon) exercise will outperform eTRE combined to morning exercise on muscle function as primary endpoint, and glucose homeostasis as secondary endpoint
Full description
Overweight, obesity, aging and menopause are all independent risk factors in the development of type 2 diabetes mellitus (T2DM). Older women with T2DM are at especially high risk for sarcopenia, i.e. loss of skeletal muscle mass and force, and cardiovascular diseases. The first line of T2DM treatment is based on lifestyle changes including weight loss and physical activity. One major current medical challenge is to find novel lifestyle therapies able to reduce cardiometabolic risk while perserving muscle mass in obese older individuals. As a result, intermittent fasting approaches, including time-restricted feeding/eating (TRF/TRE), have been offered as alternative dietary strategies that may have beneficial effects on weight control and T2DM. It has been recently observed that long-term TRF improve glucose homeostasis while perserving muscle mass and force in female obese mice. The purpose of TIMEDIAB is to demonstrate that early TRE (eTRE) combined to late (afternoon) exercise will outperform eTRE combined to morning exercise on various components of muscle health as primary endpoint, and blood glucose control, body composition, energy balance, cardiovascular risk, and metabolic health as secondary endpoints. This study will pave the way to larger scale randomized clinical trials investigating the long-term effects/benefits of such intervention and in other target populations.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Subjects on T2DM injectable medication or drugs able to induce hypoglycemia (glinides, sulfonylurea)
Subjects with HbA1c > 8%
Subjects with any of the following medical conditions:
Subjects with previous or present history of serious eating disorder
Subjects not able to understand the informed consent form or fasting diary instructions
Subjects currently participating or has participated in another study of an investigational medication or an investigational medical device within the last 30 days
Women with menopause hormone replacement therapy
Primary purpose
Allocation
Interventional model
Masking
45 participants in 3 patient groups
Loading...
Central trial contact
MONTASTIER Emilie, MD; TOMASIK Audrey
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal